Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivityNATURE COMMUNICATIONSIF15.72020-09-1533OAAI
Development of an in vitro drug-profiling platform for functional guidance of treatment decisions and identification of vulnerabilities in chemoresistant relapsed rhabdomyosarcoma tumorsCANCER RESEARCHIF16.62018-10-010PRE
Development of an in vitro drug profiling platform with primary Rhabdomyosarcoma cells for tailoring patient-specific treatmentsCANCER RESEARCHIF16.62018-07-010PRE